THE Therapeutic Goods Administration has issued a safety advisory alerting health professionals to an increased risk of death in patients with a history of major cardiovascular disease (CVD), taking Adenuric (febuxostat) tablets for their gout.
A boxed warning has been added to both the PI and CMI for febuxostat.
The above article was sent to subscribers in Pharmacy Daily's issue from 04 Oct 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Oct 19
